Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.52 |
| ▸ | JAK3 | P52333 | 4/20 | 0.52 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | IGF1R | P08069 | 4/20 | 0.48 |
| ▸ | PLK4 | O00444 | 2/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.47 |
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | WEE1 | P30291 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23906688 | 1.00 | JAK2 (0.52) | JAK2JAK3EGFRIGF1RPLK4 | |
| SCHEMBL23906567 | 0.94 | JAK2 (0.48) | JAK2JAK3EGFRIGF1RPLK4 | |
| SCHEMBL30086198 | 0.94 | JAK2 (0.48) | JAK2JAK3EGFRIGF1RPLK4 | |
| SCHEMBL30086622 | 0.93 | EGFR (0.55) | JAK2JAK3EGFRIGF1RPLK4 | |
| SCHEMBL23906540 | 0.93 | EGFR (0.55) | JAK2JAK3EGFRIGF1RPLK4 | |
| SCHEMBL23906815 | 0.92 | JAK2 (0.49) | JAK2JAK3EGFRIGF1RPLK4 | |
| SCHEMBL30086934 | 0.92 | JAK2 (0.49) | JAK2JAK3EGFRIGF1RPLK4 | |
| SCHEMBL23906665 | 0.91 | PLK4 (0.54) | JAK2JAK3EGFRIGF1RPLK4 | |
| SCHEMBL30086696 | 0.91 | PLK4 (0.54) | JAK2JAK3EGFRIGF1RPLK4 | |
| SCHEMBL25217539 | 0.91 | JAK2 (0.47) | JAK2JAK3EGFRIGF1RPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220372015-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372015-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | JAK2 1187/4885JAK3 1474/4885EGFR 545/4885 |
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | JAK2 1187/4885JAK3 1474/4885EGFR 545/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | JAK2 1187/4885JAK3 1474/4885EGFR 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.